← Ablatotech Vitals
Ophthalmology EvidenceDigest

Long-term Outcomes of Sustained-Release Drug Implants for Glaucoma Management

Ophthalmology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 2, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Sustained-release drug implants represent a promising advancement in glaucoma management by providing prolonged intraocular drug delivery, potentially improving intraocular pressure (IOP) control and patient adherence. Long-term data suggest these implants can maintain therapeutic drug levels with acceptable safety profiles, reducing the need for frequent topical medications or repeated interventions. However, variability in implant design, drug type, and patient populations studied warrants cautious interpretation. Current evidence supports sustained-release implants as a valuable adjunct or alternative in select glaucoma cases, particularly where adherence or intolerance to topical therapy is problematic (Thattaruthody et al., 2025; Sharma et al., 2021).

Clinical bottom line

Sustained-release drug implants represent a promising advancement in glaucoma management by providing prolonged intraocular drug delivery, potentially improving intraocular pressure (IOP) control and patient adherence. Long-term data suggest these implants can maintain therapeutic drug levels with acceptable safety profiles, reducing the need for frequent topical medications or repeated interventions. However, variability in implant design, drug type, and patient populations studied warrants cautious interpretation. Current evidence supports sustained-release implants as a valuable adjunct or alternative in select glaucoma cases, particularly where adherence or intolerance to topical therapy is problematic (Thattaruthody et al., 2025; Sharma et al., 2021).

What the evidence shows

Thattaruthody et al. (2025) evaluated trabeculectomy combined with a collagen matrix implant serving as a bevacizumab depot, demonstrating sustained local drug release that contributed to improved surgical outcomes and reduced fibrosis over long-term follow-up. This approach highlights the potential of implants to modulate wound healing and enhance trabeculectomy success.

Sharma et al. (2021) reported on long-term outcomes of glaucoma drainage implants in uveitic eyes concurrently treated with fluocinolone acetonide implants, noting sustained IOP control and manageable adverse effects. Their findings underscore the utility of steroid-releasing implants in complex glaucoma cases with inflammatory components.

Lee et al. (2017) described poly(ε-caprolactone) nanocapsule carriers enabling single-dose, sustained drug release for glaucoma treatment, showing promising pharmacokinetics and biocompatibility in preclinical models, suggesting potential for translation to clinical use.

Spangler et al. (2026) provide a comprehensive review of ocular pharmacology, including sustained-release systems, emphasizing advances in implant technology that improve drug bioavailability and reduce systemic exposure.

Arokia Vijaya Anand et al. (2026) discuss marine-derived polysaccharides as novel materials enhancing ocular drug delivery, potentially applicable in sustained-release glaucoma implants to optimize therapeutic efficacy and safety.

Caveats and uncertainty

Most long-term outcome data derive from small cohorts or observational studies, limiting generalizability.

Heterogeneity in implant types, drug agents, and patient populations complicates direct comparisons.

Potential complications include implant migration, local inflammation, and cataract progression, requiring vigilant monitoring.

Cost-effectiveness and patient preference data remain sparse.

Long-term effects on ocular tissues and vision require further elucidation.

How this may change practice

Sustained-release implants may reduce treatment burden and improve adherence in glaucoma patients, especially those with poor compliance or intolerance to topical drops.

Integration of implants into surgical glaucoma management could enhance outcomes by modulating wound healing and inflammation.

Ophthalmologists should consider implant options in complex cases such as uveitic glaucoma or when conventional therapies fail.

Future implant designs incorporating novel biomaterials and drug combinations may expand therapeutic possibilities.

Ongoing clinical trials and post-market surveillance will refine indications and optimize safety profiles.


References

  1. Thattaruthody F, et al. Long-term outcomes of trabeculectomy with collagen matrix implant as a bevacizumab depot. Semin Ophthalmol. 2025; DOI:10.1080/08820538.2025.2488888
  2. Sharma S, et al. Letter to the Editor: Long-term outcomes of glaucoma drainage implants in uveitic eyes with fluocinolone acetonide implants. J Glaucoma. 2021; DOI:10.1097/ijg.0000000000001816
  3. Lee CH, et al. Poly(ε-caprolactone) nanocapsule carriers with sustained drug release: single dose for long-term glaucoma treatment. Nanoscale. 2017; DOI:10.1039/c7nr03221h
  4. Spangler MD, et al. Updated ocular pharmacology for noninfectious uveitis: a comprehensive expert review. Expert Opin Pharmacother. 2026; DOI:10.1080/14656566.2026.2715704
  5. Arokia Vijaya Anand M, et al. Marine-derived polysaccharides enhance the drug delivery mechanism in the management of ocular diseases: A review. Int J Biol Macromol. 2026; DOI:10.1016/j.ijbiomac.2026.150199

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team